1. |
中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019 年版). 中国病毒病杂志, 2020, 10(1): 1-25.
|
2. |
中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010 年版). 中华肝脏病杂志, 2011, 19(1): 13-24.
|
3. |
中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015 年更新版). 临床肝胆病杂志, 2015, 31(12): 1941-1960.
|
4. |
Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int, 2009, 29(Suppl 1): 100-107.
|
5. |
Fanning GC, Zoulim F, Hou J, et al. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov, 2019, 18(11): 827-844.
|
6. |
Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology, 2007, 46(2): 395-401.
|
7. |
Kuno A, Ikehara Y, Tanaka Y, et al. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep, 2013, 3: 1065.
|
8. |
Chu CM, Hung SJ, Lin J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med, 2004, 116(12): 829-834.
|
9. |
Kamada Y, Ono M, Hyogo H, et al. Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis. Hepatol Commun, 2017, 1(8): 780-791.
|
10. |
Andreani T, Serfaty L, Mohand D, et al. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol, 2007, 5(5): 636-641.
|
11. |
贾蓉蓉, 霍荣瑞, 骆成飘, 等. 乙型肝炎表面抗原转阴患者发生肝细胞癌危险因素的系统评价. 中国循证医学杂志, 2018, 18(12): 1311-1317.
|
12. |
庄辉. 慢性乙型肝炎病毒感染的自然史及其新命名——2017年版欧洲肝病学会《慢性乙型肝炎病毒感染管理临床实践指南》解读. 中国病毒病杂志, 2017, 7(5): 321-323.
|
13. |
Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 2016, 63(1): 261-283.
|
14. |
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017, 67(2): 370-398.
|
15. |
朱鹏, 唐怡, 王宇明. 《亚太肝病学会乙型肝炎管理的临床实践指南(2015 年更新)》推荐意见. 临床肝胆病杂志, 2016, 32(3): 423-428.
|
16. |
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018, 67(4): 1560-1599.
|
17. |
World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Available at: https://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/.
|
18. |
Gara N, Zhao X, Collins MT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther, 2012, 35(11): 1317-1325.
|
19. |
Koklu S, Gulsen MT, Tuna Y, et al. Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B. Aliment Pharmacol Ther, 2015, 41(3): 310-319.
|
20. |
Viganò M, Brocchieri A, Spinetti A, et al. Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. J Clin Virol, 2014, 61(4): 600-603.
|
21. |
Wong GL, Tse YK, Wong VW, et al. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: a cohort study of 53, 500 subjects. Hepatology, 2015, 62(3): 684-693.
|
22. |
Lampertico P, Buti M, Fung S, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol, 2020, 5(5): 441-453.
|
23. |
Mak LY. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide: perhaps not as simple as we thought. Lancet Gastroenterol Hepatol, 2020, 5(5): 420-421.
|
24. |
抗乙型肝炎病毒核苷(酸)类似物不良反应管理专家委员会. 抗乙型肝炎病毒核苷(酸)类似物不良反应管理专家共识. 中华实验和临床感染病杂志(电子版), 2016, 10(5): 522-526.
|
25. |
Choi J, Kim HJ, Lee J, et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol, 2019, 5(1): 30-36.
|
26. |
Gu EL, Yu YQ, Wang JL, et al. Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study. World J Gastroenterol, 2015, 21(2): 653-660.
|
27. |
Tacke F, Kroy DC. Treatment for hepatitis B in patients with drug resistance. Ann Transl Med, 2016, 4(18): 334.
|
28. |
Rezanezhadi M, Mohebbi A, Askari FS, et al. Hepatitis B virus reverse transcriptase polymorphisms between treated and treatment-naïve chronically infected patients. Virusdisease, 2019, 30(2): 219-226.
|
29. |
Liu J, Zhang S, Wang Q, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based, cross-sectional study. Lancet Infect Dis, 2016, 16(1): 80-86.
|